LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property

LaFleur Minerals Inc. (CSE: LFLR) appointed Andrew Elinesky as CEO, effective immediately. The company also provided updates on the Beacon Gold Mill recommissioning, which is over 95% complete, and a site visit by Trafigura for potential gold doré offtake arrangements. Elinesky brings extensive executive experience in mining and financial leadership. The company's Swanson Gold Project continues to advance with positive drilling results.

LaFleur Minerals (CSE: LFLR; OTCQB: LFLRF) said it extended exclusivity with Trafigura Canada to Aug. 31, 2026 for a proposed up to C$30m prepayment facility and gold doré offtake tied to the Swanson Gold Deposit and restart of the Beacon Gold Mill. The mill’s recommissioning was ~84% complete as of July 1, 2026.

SFL Corporation ordered two 93,000 cbm ammonia carriers for $216 million, deliverable in 2028. The company also secured long-term charters with an oil major, adding $162 million to its backlog. CEO Ole B. Hjertaker highlighted the investment's accretive nature and the charterer's investment-grade status. The total fixed-rate charter backlog for 2026 exceeds $1.3 billion.

Chevron (CVX) announced senior leadership changes effective January 1, 2027. Mark Nelson will focus on strategy and business development, Eimear Bonner will lead Oil, Products & Gas, Jeff Gustavson will become CFO, and Brent Gros will head New Energies and AI strategy. CEO Mike Wirth praised the new leaders' expertise and commitment.

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.

Warren Buffett and Berkshire Hathaway each report owning 12.5% of Lennar Corporation's Class A shares, totaling 26,034,436 shares with shared voting and dispositive power. National Indemnity Company holds 10.3%, or 21,502,349 shares. Other Berkshire affiliates also report significant stakes.